Skip to content

Severe Acute Respiratory Infection - Preparedness (COVID-19 and Influenza)

Severe Acute Respiratory Infection - Preparedness

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04786301
Acronym
SARI-PREP
Enrollment
1200
Registered
2021-03-08
Start date
2020-04-30
Completion date
2022-03-31
Last updated
2021-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia, Viral

Brief summary

Severe Acute Respiratory Infection (SARI) is defined by the World Health Organization (WHO) as acute respiratory infection with a history of fever ≥38°C and cough for less than 10 days duration that requires hospital admission. SARI-PREP is a multi-center consortium funded by the CDC Foundation being assembled with the goal of providing the infrastructure to rapidly collect prospective data on clinical risks and outcomes, hospital-level stress, and biologic specimens that will aid in the rapid development of diagnostic and treatment approaches. A current example of a form of SARI to be targeted by SARI-PREP is COVID-19 the acute respiratory infectious disease caused by SARS-CoV-2 infection. COVID-19 has a broad set of manifestations and severity with a subset of affected patients developing severe disease leading to respiratory failure and other forms of organ dysfunction. As with many outbreaks of novel viral pathogens causing SARI there was no efficacious therapeutic intervention at the beginning of the COVID-19 pandemic. Furthermore, while there is emerging knowledge of clinical risks for severe COVID-19, there remains a paucity of information about the viral dynamics and host responses that might indicate a patient is at high risk for poor outcomes. The COVID-19 pandemic will be the initial target of the SARI-PREP consortium with the overall goal of developing a multi-institutional collaborative network of Acute Care Hospitals that will rapidly enroll, sample, and follow patients admitted with severe COVID-19 and to develop research protocols to rapidly determine demographic, clinical, host molecular, virologic, and institutional correlates of outcome. Overall, the information gained from this effort will help to rapidly inform and improve clinical management of epidemic/pandemic SARI patients.

Interventions

None listed

Sponsors

Centers for Disease Control and Prevention
CollaboratorFED
University of Washington
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Admission to an acute care or intensive care unit with a clinical syndrome of lower respiratory tract infection suspicious for viral SARI: * fever * cough * AND (radiographic infiltrates by imaging (chest x-ray, CT scan, etc.) OR SpO2 ≤ 94% on room air OR requiring new supplemental oxygen (above baseline if preexisting) OR requiring invasive or non-invasive mechanical ventilation). * confirmed viral cause for SARI by respiratory viral RT-PCR testing.

Exclusion criteria

* Prisoners or wards of the state * Inability to consent or lack of availability of legal surrogate * Do not attempt resuscitation/do not intubate status on admission

Design outcomes

Primary

MeasureTime frameDescription
Ventilator-free days (VFD)30 daysNumber of days alive and free of mechanical ventilation

Secondary

MeasureTime frame
Mortality28-day and 90-day
Organ failure free days30 days
World Health Organization respiratory failure ordinal score30 days

Countries

United States

Contacts

Primary ContactNikki Dodd
doddn@uw.edu206-221-0523

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026